الفهرس 
A pharmaceutical study on fast release dosage forms of a certain drug for optimization of its bioavailability
ContentsOnly 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
Epilepsy is one of the most common brain conditions that affects people worldwide. An epileptic seizure is defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Lamotrigine has Class III efficacy evidence for monotherapy of partial-onset seizures in children and Class I efficacy evidence for treatment of pediatric partial-onset seizures as an adjunctive therapy. Lamotrigine currently is approved in the United States by FDA as an adjunctive therapy for partial onset and secondarily generalized tonic-clonic seizures, crossover to monotherapy, and Lennox-Gastaut syndrome. Lamotrigine (LMG) is a phenyltriazine compound that is chemically unrelated to any of the other antiepileptic drugs. Lamotrigine (LMG) is very slightly soluble in water and slightly soluble in 0.1 N HCl. LMG is classified as a BCS class II-b drug which exhibits good solubility at the stomach acidic pH and may precipitate in the small intestine. Therefore, the aim of this study is to enhance LMG dissolution and consequently the oral BA of the drug. In recent years, much attention has been focused on lipid-based formulae to improve the oral bioavailability of poorly water-soluble compounds especially self-nanoemulsifying drug delivery systems (SNEDDS). Self-nanoemulsifying drug delivery systems are isotropic mixture of oils, surfactants, frequently in combination with a cosurfactant that have a unique ability of forming fine oil-in-water (O/W) nanoemulsion upon mild agitation followed by dilution in aqueous media, such as GI Fluids, SNEDDS spread readily in the GI Tract